Meds + Risk Factors Contribute to QTc Interval Lengthening

This article originally appeared here.
Share this content:
Meds + Risk Factors Contribute to QTc Interval Lengthening
Meds + Risk Factors Contribute to QTc Interval Lengthening

FRIDAY, July 14, 2017 (HealthDay News) -- In combination with risk factors, QTc interval-prolonging medications (QTPMs) are associated with greater QTc lengthening than QTPMs alone, according to a study published online July 10 in the Journal of Evaluation in Clinical Practice.

Khalid A. Alburikan, Pharm.D., from King Saud University in Riyadh, Saudi Arabia, and colleagues examined the contribution of risk factors alone and in combination with QTPMs to QTc interval lengthening using data from 15,792 participants with a resting, standard 12-lead electrocardiogram and one or more measures of QTc interval over four examinations. QTc lengthening was assessed using linear regression for 36,602 person-visit observations for 14,160 cohort members controlling for potential confounding variables.

The researchers found that 80 percent of person-visits had one or more risk factors for QTc lengthening. Over the four visits there was an increase in QTPM use from 8 to 17 percent. History of prolonged QTc interval and female sex correlated with the greatest QTc lengthening among those not using QTPMs (39 and 12 ms, respectively). Known QTPMs and at least two QTPMs correlated with modest but greater QTc lengthening than Possible or Conditional QTPMs, in the absence of risk factors. At least two QTPMs further increased QTc lengthening in the presence of risk factors. The association with QTc lengthening was greater for all QTPM categories combined with risk factors, compared with QTPMs alone.

"All QTPM categories augmented QTc interval lengthening associated with risk factors," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »